Related Experiment Video

Updated: Jul 18, 2026

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse
10:52

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse

Published on: April 7, 2014

Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)

Roberta P A Manzano1, Gholam A Peyman, Palwasha Khan

  • 1Department of Ophthalmology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA.

The British Journal of Ophthalmology
|December 21, 2006
PubMed
Abstract

Insights

Topical bevacizumab (Avastin) effectively reduced corneal neovascularisation in a rat model. This study shows Avastin

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Pharmacology

Background:

  • Corneal neovascularisation is a significant cause of vision impairment.
  • Current treatments for corneal neovascularisation have limitations.

Purpose of the Study:

  • To assess the efficacy of topical bevacizumab (Avastin) in an experimental model of corneal neovascularisation.
  • To evaluate bevacizumab's potential as a treatment for corneal neovascularisation.

Main Methods:

  • Chemical cauterisation was used to induce corneal injury in male Long Evans rats.
  • Bevacizumab (4 mg/ml) eye drops were administered twice daily to the treatment group.
  • A placebo (normal saline) was given to the control group.
  • Corneal neovascularisation was quantified by digital image analysis.

Main Results:

  • Bevacizumab-treated corneas showed significantly less neovascularisation (38.2%) compared to controls (63.5%).
  • The reduction in neovascularisation in the bevacizumab group was statistically significant (p<0.02).

Conclusions:

  • Topical bevacizumab (Avastin) effectively limits corneal neovascularisation after chemical injury in rats.
  • Bevacizumab demonstrates potential as a therapeutic agent for corneal neovascularisation.

More Related Videos

A Mouse Model for Corneal Neovascularization by Alkali Burn04:17

A Mouse Model for Corneal Neovascularization by Alkali Burn

Published on: June 30, 2023

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...